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Abstract  
Rationale: IL-17A is purported to help drive early pathogenesis in acute respiratory 
distress syndrome (ARDS) by enhancing neutrophil recruitment. Whilst IL-17A is the 
archetypal cytokine of T helper (Th)17 cells, it is produced by a number of 
lymphocytes, the source during ARDS being unknown.  
Objectives: To identify the cellular source and the role of IL17A in the early phase of 
lung injury 
Methods: Lung injury was induced in WT (C57BL/6) and IL-17 KO mice with 
aerosolised LPS (100 µg) or Pseudomonas aeruginosa infection.  Detailed 
phenotyping of the cells expressing RORγt, the transcriptional regulator of IL-17 
production, in the mouse lung at 24 hours was carried out by flow cytometry.  
Measurement and Main Results: A 100-fold reduction in neutrophil infiltration was 
observed in the lungs of the IL-17A KO compared to wild type (WT) mice. The 
majority of RORγt+ cells in the mouse lung were the recently identified type 3 innate 
lymphoid cells (ILC3). Detailed characterisation revealed these pulmonary ILC3s 
(pILC3s) to be discrete from those described in the gut. The critical role of these cells 
was verified by inducing injury in Rag2 KO mice which lack T cells but retain ILCs. 
No amelioration of pathology was observed in the Rag2 KO mice. 
Conclusions: IL-17 is rapidly produced during lung injury and significantly contributes 
to early immunopathogenesis. This is orchestrated largely by a distinct population of 
pILC3 cells. Modulation of pILC3s’ activity may potentiate early control of the 
inflammatory dysregulation seen in ARDS, opening up new therapeutic targets. 
Abstract word count 247 
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Introduction  
Acute respiratory distress syndrome (ARDS) is characterised by a dysregulated 
inflammatory response and neutrophil infiltration (1). Murine models of lung injury 
have demonstrated that lymphocytes rapidly influx into the lung during the early 
phase (exudative phase) (2–5) and the lymphocyte derived pro-inflammatory 
cytokine interleukin (IL)-17A is believed to contribute to pathogenesis by augmenting 
neutrophil recruitment (6–9). IL-17 is known to promote the production of various 
other inflammatory mediators including IL-6, IL-8, tumour necrosis factor (TNF)-α, IL-
1β, granulocyte-colony stimulating factor (G-CSF), monocyte chemoattractant protein 
(MCP)-1 (10). It is also known to directly drive the production of macrophage 
inflammatory protein (MIP)-2 (11).  
 
Differentiation of lymphocytes towards a type 17 programme is dependent on the 
expression of the transcription factor RORγt (12, 13). Although IL-17 was first 
described as the signature cytokine of CD4+T helper (Th)17 cells it is now known to 
also be secreted by cytotoxic CD8+T (Tc) cells, gamma delta (γδ) T cells, invariant 
natural killer (iNK)T cells and CD3- natural killer (NK) cells (14). Recently, innate 
lymphoid cells (ILCs) have emerged as a key producer of IL-17 (15). 
 
ILCs represent a family of developmentally related innate cells that are able to 
produce a broad range of cytokines. They have been ascribed a role in the defence 
of mucosal surfaces, as well as in tissue homeostasis and repair following infection 
and inflammation (16). ILCs require the common cytokine-receptor γ-chain (cγ) 
signalling (17) and IL-7R expression for their development and maintenance (18). 
Recently, a uniform nomenclature has been proposed to define sub-populations of 
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ILCs based on phenotypical and functional characteristics (19). RORγt+ ILCs, which 
express IL-17A, have been denoted as ILC3s. The essential role of ILC3s in both 
protection and immunopathology within the gut mucosa is now well recognised (16); 
however, their impact at other mucosal sites has not been reported in detail.  
 
Whilst it has been supposed that IL-17A in the lung during the exudative phase of 
ARDS is CD4+ T cell derived (6–8), a comprehensive examination of the cellular 
source of this cytokine has not been performed. Thus, the aim of this study was both 
to substantiate the role of IL-17A in the early pathogenesis of lung injury and 
determine the source of this cytokine. We confirmed the critical role of IL-17A in 
neutrophil recruitment in IL-17 knock out (KO) mice and demonstrated that ILC3s 
represent the greatest proportion of the RORγt+ cells within the lung during the acute 
phase of lipopolysaccharide (LPS)-induced lung injury. The ability of pulmonary 
ILC3s to drive neutrophil recruitment was confirmed in Rag2 KO mice, which lack all 
adaptive lymphocytes, including T cells. This is the first reported demonstration of 
ILC3s contributing to pathogenesis within the lung.  
 
Some of the results of these studies have been previously reported in the form of an 
abstract(s) (20–22). 
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Methods  
 
Additional methodological details available online.  
 
Animals 
Sex- and age- (6-14 weeks) matched C57BL/6 wild-type (WT) mice and IL-17A KO 
mice were bred in house. Recombinase activating gene 2-deficient knock out (Rag2 
KO) and Rag2 and the common cytokine receptor γ chain (cγ Rag2 DKO) mice were 
obtained from MRC National Institute for Medical Research, UK.  
 
Induction of lung injury in mice.  
Lung injury was induced in mice by the administration of either E. coli LPS (100 µg) 
(Sigma, UK- serotype 0111:B4) or 5x106 CFUs of Pseudomonas aeruginosa. Mice 
were anaesthetised and, unless otherwise stated, all mice were administered LPS 
orotracheally (o.t). Mice were intubated using a high-pressure syringe and 
MicroSprayer aerosoliser (Penn-Century. Inc. Wyndmoor, PA) and LPS or a saline 
control (50 µl) delivered into the lung. For intra-nasal (i.n) administration, 20 µl of 
LPS, bacteria or saline control were applied drop wise to the animal’s nose and were 
inhaled by normal respiration. Mice were culled at 24 h post induction, unless 
otherwise stated. To calculate the lung indices, a measure of pulmonary 
inflammation, the following equation was used; Lung index = (lung weight/body 
weight experimental) / (lung weight/body weight control).  
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Lung Histology  
Lungs were excised and fixed in 10 % formaldehyde and 3 µm sections were cut, 
stained with Haematoxylin and eosin (H&E) and mounted. A researcher blinded to 
the groups scored the damage to the lung (23). 
 
Quantification of inflammatory markers within the lung.  
Bronchoalveolar lavage fluid (BAL) was obtained by the instillation of 600 μl of PBS. 
Lung homogenate was prepared by homogenising perfused lung in 500 μl of PBS 
with a mechanical homogeniser (VWR, UK). The levels of IL-17A, IL-6, IL-23p19 
(eBioscience, UK), keratinocyte-derived chemokine (KC), IL-2 (R&D Systems, UK) 
and MIP-2 (Preprotech, USA) were determined by ELISA. Myeloperoxidase (MPO) 
activity was measured using amplifu red (Sigma-Aldrich, UK). Protein was quantified 
using Pierce BCA protein assay (Thermo Scientific, USA). Assays were read on a 
spectrophotometer (BioTek, USA). 
 
Isolation and preparation of lung cells 
Perfused lungs were harvested into Iscoves’s Modified Dulbecco’s Medium (IMDM) 
(Gibco, UK) supplemented with 10 % fetal calf serum (FCS) (Source Bioscience, UK) 
and 1 % penicillin/streptomycin (PAA, UK). The lung was finely minced and 
incubated at 37°C with 1 mg/mL Collagenase D and 200 µg/mL DNase 1 (Roche, 
Germany). The samples were then passed through a 70 µm cell strainer (Becton 
Dickinson, UK) to obtain a single cell suspension. 
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Ex vivo cell stimulation 
A single cell suspension was plated in IMDM media supplemented with 10 % FCS 
and 1 % P/S, and stimulated with IL-23 (50 ng/ml), IL-7 (10 ng/ml) (Milteni, UK) or IL-
2 (10 ng/ml) (Dynax, USA) or combinations of these cytokines. The cells were 
incubated at 37°C with 5 % CO2. At specific time points (4, 24, 48 and 72 h), the cell 
culture supernatant (750 µL) was removed and stored at -80°C until analysis for IL-
17A by ELISA. At 72 h the cells were restimulated with a commercial stimulation 
cocktail (eBioscience, UK), to induce IL-17 production, and protein transport inhibitor 
cocktail (eBioscience, UK), to prevent cellular secretion of this IL-17. After 5 h, the 
cells were analysed for the presence of intracellular IL-17, in combination with cell 
surface markers to identify specific cellular populations, using flow cytometry. 
 
Flow cytometry 
Cells were washed in FACS buffer (PBS, 2 % FCS) and the cell pellets were blocked 
for 15 minutes at room temperature with anti-CD16/CD32 (eBioscience, UK). The 
cells were surface stained with specific antibodies (detailed in the supplementary 
methods), or an appropriate isotype control, to delineate the cellular populations 
(Figure E1). The cells were washed to remove any unbounded antibody and 
fixed/permeabilised (eBioscience, UK) overnight. Intracellular antibodies targeting 
RORγt (eBioscience, UK), IL-17A or an appropriate isotype control were applied. 
After incubation cells were washed, fixed and acquired on a FACSCanto II (Becton 
Dickinson, UK). Data analysis was performed using FlowJo software (FlowJo Inc, 
OR, USA) 
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Quantitative Real Time PCR  
Lung injury was induced with LPS in WT, Rag2 KO and cγ Rag2 DKO mice and the 
lungs were collected at 4 h. RNA was extracted using TRIzol reagent (Life 
Technologies, UK), transcription and quantitative PCR were conducted using the 
Superscript III Platinum One-Step kit (Life technologies, UK), with TaqMan probes on 
a Stratagene MX3005P real-time PCR machine (Aligent Technologies, Germany). 
The fold change in IL-17A gene expression levels, relative to a PBS-treated control, 
and normalised to the housekeeping gene YWHAZ, was calculated using the 2-ΔΔCT 
method (24). 
 
Statistical Analyses 
Nonparametric data was normalised prior to analysis, results were compared using 
Student's t-test or one-way ANOVA. The exception to this is the real-time PCR 
analysis in which a Kruskal-Wallis test was used. Graphic data represents the mean 
(± SEM).  
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Results 
IL-17A plays a significant role in recruiting neutrophils to the lung  
The role of IL-17 in the early immunopathogenesis of acute lung injury was 
investigated by comparing the responses of WT (C57BL/6) or IL-17A KO mice in a 
murine model of LPS induce lung injury. Histological examination of the lungs 
demonstrated that, in WT mice LPS treatment resulted in diffuse cellular infiltration, 
whilst in the IL-17 KO lungs there were only patchy foci of inflammation (Figure 1A). 
Scoring of the lung damage observed histologically (23) revealed that there was 
significantly less injury in the IL-17 KO mice (p = 0.04) (Figure 1B). No injury was 
observed in the saline treated controls of either strain (Figures 1A & B). There was 
decreased pulmonary inflammation in the IL-17 KO mice as illustrated by a significant 
reduction in the lung index (p = 0.009) (Figure 1C). Reduced protein within the BAL 
(p = 0.04) (Figure 1D) indicates a reduction in oedema in the IL-17 KO mice. A 
significant, 100-fold reduction in the numbers of neutrophils recruited into the lungs 
was observed in IL-17A KO mice in comparison to WT mice (p = 0.03) (Figure 1E). 
There was also a significant reduction in myeloperoxidase (MPO) levels (p = 0.05) 
(Figure 1F), a marker of neutrophil activity (25).  
 
IL-6 was significantly lower in the IL-17 KO mice (p = 0.04) (Figure 1G) than in the 
WT controls. Levels of KC, the murine homolog of IL-8, were not significantly 
reduced (p = 0.09) (Figure 1H), however, levels of the IL-17 dependant neutrophil 
chemoattractant MIP-2 (11) were significantly reduced (p = 0.01) (Figure 1I).  
 
IL-17 driven recruitment of neutrophils into the lung was also apparent when bacterial 
pneumonia was used to induce lung injury. There was a significant reduction in the 
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percentage of neutrophils detected within the BAL (p = 0.005) (Figure 2A). Again, 
demonstrating the downstream effects of IL-17, a significant reduction in the levels of 
MIP-2 (p = 0.04) were observed (Figure 2B). The diminished neutrophilia within the 
lung resulted in a trend towards reduced damage, indicated by protein levels in the 
BAL (p = 0.052) (Figure 2C), and disease severity (IL-6 p = 0.1) (Figure 2D). There 
was no significant difference in the bacterial burden within the lungs of the WT and 
IL-17 KO mice (data not shown).  
 
ILCs are the predominant RORγt+ cells detected within the lung during the acute 
phase of lung injury. 
To establish the cellular source of the IL-17, injury was induced in C57BL/6 mice and 
lung cells were harvested 24 hours post administration. The expression of RORγt, 
was determined using flow cytometry. LPS administration resulted in a significant 
increase in the number of RORγt+ cells (p = 0.001) within the lung, in comparison to 
PBS treated control mice (Figure 3A). When the phenotype of the gated RORγt+ cells 
was examined, the frequency of NKT, NK and γδ T RORγt+ cells was low (Figure 3B 
& E1). The lung leukocyte RORγt+ population consisted predominantly of ILC (28.6 % 
± 5.9) and αβT cells (30.9 % ± 10.1) (Figure 3B & E1). The αβT cells were equally 
divided between CD4+ (Th17) and CD8+ (Tc17) cells (p = 0.43) (Figure. 3B & E1). To 
further verify IL-17 production in the RORγt+ cells, injury was induced and the lungs 
were harvested. The cells were rested and then restimulated ex-vivo to induce a 
further burst of IL-17 production. Golgi block prevented cellular release of the IL-17,  
thus allowing the identification of IL-17+ cells. Both RORγt+ ILCs and CD4+ T cells 
produced IL-17A but this was not observed in CD8+ cells (Figure 3C).  
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A significant augmentation of the ILC3 population was observed in the lung post-LPS 
exposure (p = 0.01) (Figure 4A) and these cells far outnumbered the Th17 cells 
detected in the lung (p = 0.009) (Figure 4B). However, no significant difference in the 
median fluorescence intensity of IL-17A expression, an indicator of production per 
cell, was detected between the CD4+ cells and ILCs stimulated ex vivo (p = 0.9) 
(Figure 4C), indicating ILC3s are the predominant source of IL-17.  
 
To further verify that ILC3s are the critical source of IL-17, RNA expression levels 
were examined in WT, Rag2 KO (lacking T cells, but retaining ILCs) and cγ Rag2 
DKO (lacking both T cells and ILCs) mice using quantitative real-time PCR. In the cγ 
Rag2 mice in which both adaptive and innate lymphocytes are absent (cγ Rag2 
DKO) IL-17A (Figure 5A) was not detected.  When ILCs are present (Rag2 KO) mice, 
IL-17 expression was not significantly different from the WT controls (p = 0.4) (Figure 
5A). Furthermore, there was no significant difference in the lung index (p = 0.5) 
(Figure 5B) or IL-17 induced cytokine MIP-2 (p = 0.2) (Figure 5C), in Rag2 KO mice 
compared to WT controls. The Rag2 KO mice showed elevated levels of neutrophil 
infiltration (p = 0.02), KC levels (p = 0.002) and a trend towards increased IL-6 (p = 
0.06) following LPS induced lung injury.  
 
IL-17A production in lung lymphocytes is induced by IL-23 and amplified by IL-2.  
IL-23 is known to drive IL-17 production (14), whilst IL-2 and IL-7 both utilise the 
cytokine-receptor common γ-chain known to be involved in ILC signalling (17). To 
examine the regulation of IL-17 production in ILC3s, cells were harvested from the 
lungs of LPS exposed mice and cultured in the presence of rIL-23, rIL-2 and rIL-7 or 
combinations thereof. The levels of IL-17A in the cell culture supernatant at 4, 24, 48 
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and 72 h were quantified by ELISA. IL-17A production continued to increase up to 72 
h (Figure 6A). No significant difference was observed in IL-17A levels when the cells 
were stimulated with all three cytokines or with just IL-23 and IL-2 (p = 0.94) (Figure 
6B), suggesting there is little role for IL-7 in induction of IL-17A production by ILC3s 
in this model. Whilst IL-23 alone induced IL-17A release, this was significantly 
augmented when IL-2 was added (p = 0.004) (Figure 6B). To verify that the IL-2 was 
not preferentially driving T cell production of IL-17A, intracellular flow cytometry was 
used to demonstrate IL-17A production by the ILC3s after 72 h stimulation. No 
differences were observed in the contribution of T cells to the IL-17A production 
when the cells were stimulated with IL-2 compared to IL-23 (Figure 6C). When ILC3s 
were cultured with IL-2 there was a significant increase in the percentage of cells 
expressing the receptor for IL-23 (p = 0.03) (Figure 6D). Following the induction of 
acute lung injury in vivo, elevated levels of IL-23p19 were detected in murine BAL (p 
= 0.04) (Figure 6E). A significant elevation in IL-2 levels is observed in the mice at 12 
h in LPS-treated mice compared to control-treated animals (p = 0.02) (Figure 6F).  
 
Phenotypic analysis of the lung ILCs 
To further phenotype the RORγt+ ILCs in the lung during LPS induced lung injury, a 
detailed characterisation of the expression of a number of surface receptors was 
carried out. We identified a population of cells within the lung during the exudative 
phase of lung injury that were defined as ILC3 based on the lack of expression of 
lineage markers (Lin-) and expression of CD45 and RORγt (Figure E2A). The 
expression of ILC surface markers on these cells was characterised (Figure E2B-G & 
Table 1). The most abundant RORγt+ ILCs characterised resembled the NCR- ILC3s 
(58 %) described in the gut (12), with the exception that the cells detected in the lung 
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were CD117 (c-KIT) positive. The second most frequent cell type had the surface 
marker expression profile described for LTi cells (21 %) (26). There was also a small 
population of NCR+ ILC3s (3 %) identified (27). For both the LTi cells and NCR+ 
ILC3s there was no disparity in the expression of surface markers compared to cells 
from the gut. All three populations of RORγt+ ILCs also expressed chemokine 
receptor 6 (CCR6).  
 
Discussion 
Neutrophils play an essential role in the innate immune response during infection and 
inflammation; and their infiltration into the airspace is a hallmark feature of ARDS (1). 
It has been suggested that the proinflammatory cytokine IL-17A plays a role in 
neutrophil recruitment within the lung during lung injury (6–8). Utilising an IL-17 KO 
mouse model (28), the pivotal role of IL-17A in early neutrophil recruitment into the 
lung following LPS exposure was confirmed.  
 
During lung injury the IL-17 KO mice also showed reduced levels of damage using a 
number of the criteria set out by Matute-Bello et al (23). There was also abrogation of 
IL-6 production, a surrogate marker of disease severity in murine models (29, 30). 
MIP-2 is a potent neutrophil chemoattractant and has previously been shown to play 
a key role in ARDS (31). Expression of MIP-2 is known to be driven by IL-17 via the 
MAPK pathway (11), offering an insight into the mechanism by which IL-17 is able to 
exert it’s effects during early immunopathogenesis of lung injury. Similar results were 
observed when lung injury was induced with a clinically relevant bacterial pneumonia 
model. There was a significant reduction in the percentage of neutrophils detected 
within the BAL of the IL-17 KO mice, and reduced MIP-2 levels. This is consistent 
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with findings using the caecal ligation puncture (CLP) model of polymicrobial sepsis, 
where IL-17 neutralisation led to a decrease in pro-inflammatory cytokines (TNFα, IL-
1β and IL-6); and surprisingly, a decrease in bacteraemia (32). This suggests that IL-
17 neutralisation may have therapeutic potential for the treatment of ARDS, 
particularly given anti-IL-17 therapy has shown efficacious in experimental models of 
sepsis (33).  
 
It has been purported that the source of IL-17A in ARDS is CD4+ T cells; however 
there is lack of detailed analysis of the specific cellular source. Differentiation of 
lymphocytes towards a type 17 programme is dependent on the expression of the 
master regulator transcription factor RORγt (14). Therefore, we phenotyped cells 
expressing the transcription factor RORγt within the mouse lung during the early 
phase of lung injury. It was demonstrated that ILCs represented the largest 
proportions of RORγt+ cells within the lung during the early pathogenesis. Whilst both 
CD4+ and CD8+ αβ T express RORγt, CD8+ cells did not produce IL-17A upon ex-
vivo restimulation. This suggests that although predisposed to producing IL-17, 
Tc17s do not specifically produce IL-17A in this model. It has previously been 
suggested that, in the presence of Th17 cells, Tc17 cells have reduced functionality 
due to IL-2 released by CD4+ T cells (34). This may explain the observation that Tc17 
cells contribute little to IL-17 production in this setting.  
 
It was shown that ILC3s were the predominant IL-17A producing cells in the lung 
during LPS induced lung injury. This conclusion was based on the detection of 
significantly higher absolute numbers of RORγt+ pILC3s compared to CD4+ T cells, 
but no difference in the median fluorescence intensity, an estimation of the levels of 
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IL-17A expression per cell, in CD4+ T cells and ILC3s. To further verify the critical 
role of ILCs in lung injury, we examined the relative expression of IL-17 using 
quantitative real-time PCR. Although there was a reduction in the relative expression 
in the Rag2 KO mice, which lack T cells, it was only when ILCs were also absent (cγ 
Rag2 DKO) that a significant reduction compared to the WT animals was observed. 
The proposal of ILC3s as the main source of IL-17A is corroborated by previous 
studies which have demonstrated that IL-17- induced neutrophil infiltration occurs in 
SCID mice lacking T cells (6) and the majority of IL-17+ cells within the BAL are CD3- 
(8, 9). This is mirrored in the oral mucosa, where ILC3s have been shown to be the 
predominant source of IL-17 in response to Candida infection (35). There were 
significantly higher numbers of neutrophils and KC levels detected in the lungs of 
Rag2 KO mice compared to WT controls. This may indicate that the ILC3 cells are 
normally restrained by Tregs or Bregs, both of which are absent in the Rag2 KO 
mice. Whilst ILCs predominated the early response during acute lung injury, this 
appears to be supersede at later time points by an adaptive αβ T cell response (36). 
 
ILCs are known to be dependent on the common- receptor γ chain of the IL-2 family 
of cytokines for their development (17) and require signalling through the IL-7 
receptor subunit alpha (IL-7Rα) (18). Additionally, IL-23 has also been shown to 
direct and maintain IL-17 production in ILCs (26). Investigation of the role of these 
cytokines in IL-17A production by ILC3 from LPS primed lungs demonstrated that 
there is little involvement of IL-7 in this model, despite these cells expressing high 
levels of IL-7Rα (CD127). In contrast, IL-23 was shown to drive IL-17A production 
and this was significantly increased by IL-2. This IL-2 augmentation of IL-17A levels 
could be seen as counter intuitive, given reports that IL-2 inhibits Th17 differentiation 
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(37). However, cytokines are known to have a differential effect on developing versus 
committed Th17 cells (38), and there have been reports of IL-2 expansion of 
differentiated Th17 cells (39). Furthermore, IL-2 enhances IL-33 driven IL-9 
production in ILC2 cells (40). Incubation with IL-2 increased the percentage of ILC3s 
expressing IL-23 receptor. During the induction of lung injury there was an early peak 
of IL-2 detected in the murine BAL, presumably this primes the cells for optimal 
response to IL-23 and subsequent IL-17 production. Whilst the synergistic effects of 
IL-6, IL-23 and low concentrations of TGF-β on the expression of IL-23 receptor have 
been characterised (41), its upregulation by IL-2 has not been previously described.  
 
A uniform nomenclature has been proposed in order to clarify ILC populations based 
on phenotypical and functional characteristics (19). The group 3 ILCs produce IL-
17A, with LTi cells being the prototypical cells in this group (26). Other distinct 
subsets have been characterised, those expressing the natural killer cell receptor 
(NCR) NKp46 are denoted NCR+ ILC3s and there is also a population that lack NCR, 
like LTi cells, but are CD4- (19). We examined the expression of a number of cell 
markers that have previously been used to define ILC populations. Within the lung 
the ILCs identified were largely comparable to those previously defined in the gut (27, 
42). However, there was some variance in the expression of surface markers; 
therefore we have termed the unique population identified within the inflamed lung as 
pulmonary ILC3s (pILC3s).  
 
In T cells, the expression of CCR6 is limited to Th17 and Treg cells (43). ILC3s in the 
gut have been shown to express CCR6 (44). We have demonstrated that pILC3s 
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within the lung also expressed CCR6, it therefore seems likely that, as with T cells, 
CCR6 mediates homing of RORγt+ ILC3s into tissues and inflammatory sites (43).  
 
Previous studies have demonstrated that ILC2s interact with the lung epithelium and 
are involved in both repair and pathogenesis (45–47). In contrast, ILC3s had 
previously only been described playing a protective role in the lung. They function in 
the repair of the lung following influenza A infection (48) and protect against 
secondary bacterial infection (49). To the best of our knowledge, this is the first report 
of ILC3s driving inflammation within the lung and it is clear that an inappropriate 
response is capable of resulting in immunopathology in the lung, as has been 
previously described in the gut (12).  
 
In conclusion, the significant decrease in neutrophil infiltration in IL-17KO mice in an 
LPS-induced model of lung injury confirms the previously surmised key role of this 
cytokine in the early immunopathogenesis. Most notably, it was demonstrated that 
the predominant source of this proinflammatory cytokine during lung injury was the 
innate immune system. Recognition of the role of pILC3s in initiating acute lung 
inflammation may offer new therapeutic opportunities as modulation of ILCs’ function 
may allow early control of inflammatory dysregulation. 
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Legends 
TABLE 1. Phenotypic markers of lung innate lymphoid cells. Lin- CD45+ RORγt+ 
lung ILC3s were analysed by flow cytometry and the expression of cell surface 
markers associated with ILC subsets were characterised (Figure E2); 3 discrete 
populations were identified. The data is representative of three independent 
experiments, each experiment utilised n = 3 mice pooled. LTi, lymphoid tissue 
inducer cell; NCR, natural cytotoxicity receptor; SCA-1, stem cell antigen-1; NK, 
natural killer.  
 
FIGURE 1. IL-17 plays a key role in the recruitment of neutrophils during the 
early pathogenesis of LPS induced lung injury. Following (24 h) LPS 
administration there was a difference in the levels of injury detected within the lungs 
of WT C57BL/6 or IL-17KO mice. Representative images from H&E stained lungs (x 
20 magnification) are shown (A) along with scoring based on neutrophils in the 
alveolar space, neutrophils in the interstitial space, hyaline membranes, 
proteinaceous debris filling the airspaces and alveolar septal thickening (23) (n = 3 
mice per treatment) (B). The lung index (Lung index = (lung weight/body weight 
experimental) / (lung weight/body weight control)), indicative of pulmonary 
inflammation, was calculated (n = 6 per group) (C). BAL was collected and the levels 
of protein detected (n = 18-20 per group) (D). Neutrophils (Ly6-G+ CD11b+) were 
analysed by flow cytometry and the absolute numbers of BAL neutrophils calculated 
(n = 6-10 per group) (E). Levels of MPO activity (F), IL-6 (G) KC (H) and MIP-2 (I) 
were measured in the BAL fluid (n=10-20 per group). *p < 0.05. 
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FIGURE 2. Reduced neutrophil recruitment is observed in IL-17 KO mice 
following bacterial pneumonia induced lung injury. WT C57BL/6 or IL-17 KO 
mice were inoculated intranasally with 5 x 106 CFUs of Pseudomonas aeruginosa 
(PA01), BAL was collected 24 h post inoculation and the percentage of neutrophils 
(Ly6-G+ CD11b+) analysed by flow cytometry (A). Total protein (B), IL-6 (C) and MIP-
2 (D) levels were quantified (n = 8 per strain). *p < 0.05. 
 
FIGURE 3. RORγt+ lymphocytes are recruited to the lung of mice during LPS-
induced lung injury. Lung cells were harvested 24 h post LPS administration and 
flow cytometry was performed. The absolute number of RORγt+ lung cells was 
calculated using the total lung cell count and the percentage of RORγt+ cells (A). The 
RORγt+ cells within the lung were phenotyped and the percentage of NK cells (CD3- 
NK1.1+), NKT cells (CD3+ NK1.1+), Th17 cells (CD3+ NK1.1- CD4+), Tc17 cells (CD3+ 
NK1.1- CD8+), γδ T cells (γδ TCR+) and ILCs (CD45+ Lin- NK1.1- γδ TCR-) 
determined (B). The in vivo LPS primed cells were cultured and restimulated to 
increase IL-17 production, in the presence of a golgi block to prevent cytokine 
secretion. Intracellular cytokine staining, using either anti-IL-17A or an isotype control 
was performed. The isotype control, which demonstrates the levels of non-specific 
binding, was used to position the positive gate and the production of IL-17A in 
RORγt+ cells (black) and RORγt- cells (grey) was plotted against side scatter (SSC) 
assessed (C) (n = 3 mice pooled, in three independent experiments). *p < 0.05. 
 
 
 
25 
FIGURE 4. There are significantly more RORγt+ ILCs than Th17 cells in the lung 
during the early stages of LPS induced lung injury. LPS, or saline control, was 
administered o.t to C57BL/6 mice. Lungs were harvested after 24 h and flow 
cytometry performed. LPS administration resulted in a significant increase in the 
absolute numbers of RORγt+ ILC3s within the lung (A). Higher numbers of ILC3s 
than Th17 (CD4+) T cells were detected following LPS administration (B). When 
these cells were restimulated ex vivo there was no difference in the median 
fluorescent intensity (MFI), an indication of the amount of expression per cell, of IL-
17A expression between ILC3s and Th17 cells (C) (n=3 mice/group pooled, three 
independent experiments performed). * p < 0.05.  
 
FIGURE 5. Induction of lung injury in mice lacking T cells, confirms the critical 
role of ILC in IL-17 production and neutrophil recruitment. The lung of WT, Rag2 
KO (lacking T cells) and cγ Rag2 DKO (lacking both T cells and ILCs) were 
harvested 4 h post LPS exposure. The expression of IL-17A was analysed by real-
time PCR; the data were normalised using the house-keeping gene YWHAZ and the 
2-ΔΔCT used to analyse the expression levels relative to a PBS control (WT and Rag2 
KO n = 13 per strain, cγ Rag2 DKO n = 6) (A). Lung injury was induced in WT and 
Rag2 KO mice by i.n administration of LPS; after 24 h the lungs were harvested and 
weighed to calculate the lung index (B). The lungs were homogenised and the levels 
of MIP-2 (C), the total number of neutrophils (D), IL-6 (E), and KC (F) concentration 
calculated (n = 6 per strain) .* p < 0.05.  
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FIGURE 6. IL-23 induces IL-17A production in lung lymphocytes which is 
amplified in the presence of IL-2. Cells harvested from the lungs of LPS treated 
mice were incubated ex vivo with rIL-23, rIL-2 and rIL-7 or combinations of these 
cytokines. The cell culture supernatants were sampled at 4, 24, 48, 72 h and the 
level of IL-17A quantified (A) (n=3 mice pooled, 6 replicates). Cells were cultured with 
all possible combinations of cytokines for 72 h and the levels of IL-17A determined 
(B) (n=3 mice pooled, repeated 3 times), *p < 0.05.. Flow cytometry was used to 
stain intracellular IL-17A levels following stimulation with IL-2 and IL-23 and to 
determine the percentage of IL-17+ cells which were ILC3s (C). The percentage of 
ILC3s expressing IL-23R on their surface following culture with IL-2 was analysed by 
flow cytometry (D) (n = 3 mice pooled, in triplicate). Following the induction of acute 
lung injury in C57BL/6 mice the levels of IL-23p19 within the BAL at 24 h was 
assessed (E) (n = 10-16/group, *p < 0.05), IL-2 levels in the BAL were quantified at 8, 
12 and 24 h post LPS exposure (F) (LPS n = 4 per time point, PBS n = 3 per time 
point, *p < 0.05). 
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TABLE 1 
ILC Group 3 
subset 
pILC3 LTi 
cells 
NCR+ 
ILC3 
Marker 
Lin- CD45+ RORγt+ + + + 
CD90 (Thy1) + + + 
Sca1 (Ly6A) + - - 
NKp46 (NCR) - - + 
CD117 (c-Kit) + + + 
CD127 (IL-7Rα) + + + 
CD4 - high low 
CCR6 + + + 
Percentage  
detected  
58 21 3 
Reference  This 
study 
(19, 24) (19, 25) 
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Supplementary Methods  
Mice 
All studies were approved by Queen’s University Belfast’s ethical committee and 
were conducted in accordance with the UK Home Office regulations. Sex- and age- 
(6-14 weeks) matched C57BL/6 wild-type (WT) mice and IL-17A KO mice (kindly 
provided by Dr Yoichiro Iwakura, Institute of Medical Science, The University of 
Tokyo, Japan) (1) were bred in house. Recombinase activating gene 2-deficient 
(Rag2 KO) mice (2) on C57BL/6 background and mice deficient in both Rag2 and the 
common cytokine receptor γ chain (cγ Rag2 DKO) (3) on a Balb/c background were 
kindly provided by Dr Mark Wilson, MRC National Institute for Medical Research, UK. 
Rag2 KO lack T cells but retain ILCs, in contrast cγ Rag2 DKO lack both T cell and 
ILCs.  
 
Induction of lung injury in mice.  
Lung injury was induced in mice by the administration of either E. coli LPS (100 µg) 
(Sigma, UK- serotype 0111:B4) suspended in injection grade saline, or inoculation 
with 5 x 106 CFUs of Pseudomonas aeruginosa (PA01, kindly provided by Prof Scott 
Bell, Australian Infectious Diseases Research Centre). This clinically relevant 
bacterial pneumonia model was chosen as it induces significant levels of lung injury 
(4). In contrast, in the widely used CLP model, it has recently been demonstrated that 
lung injury is not the primary cause of mortality in the mice (5). 
 
Mice were anaesthetised with xylazine and ketamine by intraperitoneal (i.p.) injection. 
Unless otherwise stated, all mice were administered LPS via the orotracheally (o.t) 
route. Mice were intubated using a high-pressure syringe and MicroSprayer 
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aerosoliser (Penn-Century. Inc. Wyndmoor, PA) (6). LPS or a saline control were 
delivered into the lung (50 µl). For intra-nasal (i.n) administration, 20 µl of LPS, 
bacteria or a saline control were applied drop wise to the animal’s nose, these were 
inhaled by normal respiration. Following i.n administration, animals became 
tachypneic, they were held in an upright position until their breathing normalised to 
ensure maximal delivery into the lungs. Mice were culled at 24 h post induction, 
unless otherwise stated. To calculate the lung indice, a measure of pulmonary 
inflammation (7), the following equation was used;  
 
Lung index =  lung weight/body weight experimental 
    lung weight/body weight control 
 
 
Lung Histology  
Lungs were excised and fixed in 10 % formaldehyde over night at room temperature 
for histological processing. Lung tissue was embedded in paraffin by members of the 
core tissue unit (CTU) in QUB and 3 µm sections were sectioned and floated onto a 
saline coated slide (MSC, Ireland) and dried in an oven at 60°C. The sections were 
de-waxed with Histoclear (National Diagnostics, US), rehydrated in decreasing 
concentrations of alcohol, before final transfer to distilled water for 5 minutes. 
Sections were stained with Haematoxylin and eosin (H&E), dried then mounted using 
DPX mounting media (HD Supplies, UK) and cover slips applied. DPX was allowed 
to solidify overnight and sections were then examined microscopically. A researcher 
blinded to the mouse strain/treatment group of each scored the damage to the lung in 
≥ 5 field of view for each section using the system outlined by Matute-Bello et al (8). 
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Quantification of inflammatory markers within the lung.  
BAL was obtained by the instillation of four successive 150 µL aliquots of ice cold 
sterile PBS into the mouse lung and the recovered fluid from each wash was pooled 
for each individual animal. Samples were stored on ice until cell-free supernatant was 
obtained by centrifugation (300 x g, 10 minutes, 4°C). For the preparation of lung 
homogenate, lungs were harvested and stored on ice. They were homogenised in 
500 μl of sterile, ice cold PBS with a mechanical homogeniser (VWR, UK). The 
sample was then gently centrifuged (300 x g, 10 minutes, 4°C) to pellet the cellular 
material and the supernatant was collected. All samples were stored at -80oC until 
analysed.  
 
ELISA was used to quantify IL-17A, IL-6, IL-23 (eBioscience, UK), keratinocyte-
derived chemokine (KC), MIP-2 (Preprotech, USA); IL-2 was quantified by luminex 
assay (Invitrogen, UK), all following the manufacturer protocols.  
 
Myeloperoxidase (MPO) activity was measured in the BAL fluid collected from murine 
in vivo experiments. MPO from human leukocytes was used to generate a standard 
curve (0.0625 U/mL - 0.000977 U/mL). The standards and samples were diluted 
(1:50) in assay buffer (potassium phosphate dibasic solution 2.5 μM). The samples 
were then added to a black 96-well plate (Sterilin, UK) with 50 µL of reaction cocktail 
(50 µM amplifu red, 20 mM hydrogen peroxide in assay buffer). The plate was 
incubated at room temperature in the dark for 60 minutes before measuring the 
fluorescence at excitation 530-570 nm and emission at 590-600 nm. All components 
were purchased from Sigma, UK. 
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Total protein concentration was measured in the BAL fluid against a standard curve 
of pre-determined bovine serum albumin (BSA) standards ranging from 2 mg/mL to 
31.25 μg/mL (Thermo Scientific, UK) using Pierce BCA protein assay (Thermo 
Scientific, UK) as stated in the manufacturer’s protocol. Assays were read at 450 nm 
on a spectrophotometer (BioTek, U.S.A). 
 
Isolation and preparation of lung cells 
Lungs were perfused with cold sterile PBS through the right ventricle of the heart 
then harvested into Iscoves’s Modified Dulbecco’s Medium (IMDM) (Gibco, UK) 
supplemented with 10 % fetal calf serum (FCS) (Source Bioscience, UK) and 1 % 
penicillin/streptomycin (PAA, UK). To prepare a single-cell suspension, the lung was 
finely minced and incubated at 37°C in media, supplemented with 1 mg/mL 
Collagenase D and 200 µg/mL DNase 1 (Roche, Germany), for 1 hour with constant 
agitation. After incubation, the samples were passed through a 70 µm cell strainer 
(Becton Dickinson, UK), centrifuged (300 x g, 5 minutes, RT) and the red blood cells 
lysed. A live-dead cell count was then performed on the single cell suspension using 
a Countess automated cell counter (Invitrogen, UK). 
 
Ex vivo cell stimulation 
Single cell suspension prepared from the lungs were plated in IMDM media 
supplemented with 10 % FCS and 1 % P/S, and stimulated with IL-23 (50 ng/ml), IL-7 
(10 ng/ml) (Milteni, UK) or IL-2 (10 ng/ml) (Dynax, USA) or combinations of these 
cytokines. The cells were incubated at 37°C with 5 % CO2. At specific time points (4, 
24, 48 and 72 h), the cell culture supernatant (750 µL) was removed and stored at -
80°C until analysis for IL-17A by ELISA. At 72 h the cells were treated with a 
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commercial PMA/ionomycin based stimulation cocktail (eBioscience, UK), to 
restimulate IL-17 production, and protein transport inhibitor cocktail (eBioscience, 
UK), to prevent cellular secretion of this IL-17. After 5 h, the cells were washed and 
stained for analysis of intracellular IL-17, in combination with cell surface markers to 
identify specific cellular populations, by flow cytometry. 
 
Flow cytometry 
Cells were washed in FACS buffer (PBS, 2 % FCS) and the cell pellets were blocked 
for 15 minutes at room temperature with anti-CD16/CD32 (eBioscience, UK), then 
washed again. For cell surface staining cells were incubated for 30 minutes at room 
temperature with the antibodies against the following: Ly-6G PE, CD11b APC-efluor 
660, CD4 PE-Cy7, CD8 PerCP-Cy5.5, NK1.1 PE, biotinylated anti-hematopoietic 
lineage panel with Streptavidin APC-efluor 780, CD3 APC-Cy7/Pacific Blue, CD8 
Pacific Blue, γδ TCR APC, CD25 APC-Cy7, CD45 FITC, CD90 APC, CCR6-Alexa 
Fluor  647, c-KIT APC, NKp46 PE-Cy7, CD127 brilliant violet 421, Sca-1 PE and IL-
23R PE. For intracellular staining, cells were surface-stained then fixed/ 
permeabilised using the Foxp3 staining buffer set (eBioscience, UK) according to 
manufacturer’s instructions. Following overnight permeabilisation, antibodies 
targeting; RORγt PerCP-efluor 710 or IL-17A Pacific blue/ PE were used. Full details 
of the antibodies utilised within this study are provided in Table E1. Cells were 
acquired within 24 hours of staining on a FACSCanto II (Becton Dickinson, UK) and 
data analysed using FlowJo software (FlowJo Inc, OR, USA). 
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Quantitative Real Time PCR  
Lung injury was induced with LPS in WT, Rag2 KO and cγ Rag2 DKO mice, at 4 h 
the lungs collected and stored in RNAlater™ RNA Stabilisation Reagent (Qiagen, 
Crawley, UK) at −20°C until ready for use. Total RNA was extracted using the acid 
phenol method with TRIzol® (Life technologies, UK) according to the manufacturer’s 
protocols before resuspension in RNase-free water. Reverse transcription and 
quantitative PCR were conducted using the Superscript® III Platinum® One-Step 
Quantitative RT-PCR System kit (Life technologies, UK) following the manufacturer’s 
instructions. Briefly, 4 µl of extracted RNA were added in a PCR plate to 24 l of 
Reaction mix containing the Taq polymerase, ROX as a reference dye and the 
primer/TaqMan® mix for either IL-17A or the house-keeping gene YWHAZ. The plate 
was briefly centrifuged and the reaction performed on a Stratagene MX3005P real-
time PCR machine (Aligent Technologies, Germany) by a cycle of 15 min at 50oC 
and 2 min at 95oC for the reverse transcription followed by 45 cycles of 15 s at 95oC 
and 30 s at 60oC. Each sample was run in triplicate for both primers and a non-
template control was performed. The fold change in IL-17A gene expression levels, 
relative to a PBS treated control, and normalised to the housekeeping gene YWHAZ, 
was calculated using the 2-ΔΔCT method (9). 
 
Statistical Analyses 
Normally distributed results were compared using Student's t-test or one-way 
ANOVA. Nonparametric data was normalised prior to analysis, either by log 
transformed analysis or arcsin transformed in the case of percentage data. The 
exception to this is the real-time PCR analysis in which mouse strains were 
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compared using a Kruskal-Wallis test. All statistical analyses were performed using 
Prism GraphPad software v.4.0. Graphic data represents the mean (± SEM).  
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Online supplementary figure legends 
SUPPLEMENTARY TABLE E1. Details of the antibodies utilised within this 
study.  Provided is the name, clone, conjugated fluorochrome, isotype and supplier 
of each all the antibodies that were utilised during this study.   
 
SUPPLEMENTARY FIGURE E1. Flow cytometry gating strategy for determining 
the RORγt lymphocytic populations. Lung cells were harvested 24 h after i.t LPS. 
Lymphocytes within the lung were characterised. In all histograms both the antibody 
(black) and an isotype control (red) are shown, for RORγt+ a fluorescence minus one 
(light red) control was also included. . Based on the cells forward and side scatter 
properties a lymphocyte gate was drawn. CD45 staining was used to verify these 
cells were leukocytes To establish the phenotype of these RORγt+ cells populations 
were delineated as γδ TCR+ (γδ T cells) or Lin- (ILC3s). CD3 expression was then 
used to define the remaining cell populations; the CD3 positive population was then 
separated into CD3+ NK1.1+ (NKT cells), CD3+ CD4+ NK1.1- (CD4+ Th17 cells) or 
CD3+ CD8+ NK1.1- (CD8+ Tc17 cells). The CD3 negative population was used to 
define the CD3- NK1.1+ (NK cells).  
 
SUPPLEMENTARY FIGURE E2; Flow cytometric gating strategy for identifying 
RORγt+ ILCs and phenotyping based on the expression of typical of known 
group 3 innate lymphoid cell populations. (A) ILCs recruited to the lung during 
acute lung injury were identified as being Lin-(CD3-Gr-1-CD11b-TER-11-B220-NK1.1-
γδTCR-CD11c-), CD45+, RORγt+. Expression of RORγt shown in the dot plot is 
compared to an isotype control (red). The expression of cell surface markers (B) 
CD90 (alloantigen Thy-1), (C) Sca-1, (D) NKp46 (NCR), (E) CD117 (c-kit), (F) CD127 
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(α- chain of the receptor for IL-7), (G) CCR6. (black line) compared to isotype control 
(red shaded) associated with ILC3 subsets characterised (representative histograms 
shown). The data is representative of three independent experiments, each 
experiment utilised n=3 mice pooled. 
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SUPPLEMENTARY TABLE E1 
Antibody Clone Fluorophore Isotype control  Supplier 
CD117 (Ckit) 2B8 APC Rat IgG2b κ  BioLegend 
CD11b M1/70 APC efluor 660  Rat IgG2b eBioscience 
CD127(IL-7R) A7R34 BV421 Rat IgG2a κ BioLegend 
CD196 (CCR6) 29-2L17 Alexa Fluor 647  
Armenian 
Hamster IgG  
BioLegend 
CD25 PC61 APC-Cy7 Rat IgG1   BioLegend 
CD3 17A2 ; 145-2C11 
Pacific Blue/ 
APC-Cy7 
Rat IgG2b κ/ 
Armenian 
Hamster IgG 
BioLegend 
CD4 GK1.5 
PE-Cy7/  
Pacific Blue 
Rat IgG2b, κ eBioscience 
CD45 30-F11 FITC Rat IgG2b, κ BioLegend 
CD8a 53-6.7 
Pacific Blue/  
PerCP-Cy5.5 
Rat IgG2a κ 
BioLegend/ 
eBioscience 
CD90.2 30-H12 APC Rat IgG2b, κ BioLegend 
IL-23R O78-1208 PE Rat IgG1   
Becton 
Dickenson 
Ly-6A/E (Sca-1) D7 PE Rat IgG2a κ BioLegend 
Ly-6G (GR-1) RB6-8C5 PE Rat IgG2b, κ eBioscience 
NK1.1 PK136 PE Mouse IgG2a κ eBioscience 
NKp46 (CD335) 29A1.4 PE-Cy7 Rat IgG2a κ BioLegend 
γδTCR GL3 APC 
Armenian 
Hamster IgG 
BioLegend 
Mouse Hematopoietic 
Lineage Panel: CD3, 
CD45R, CD11b, 
Erythroid marker, Ly6G 
Supplemented with 
NK1.1 & γδTCR 
145-2C11, RA3-6B2, 
M1/70, TER-119, RB6-
8C5 
 
 
PK136, GL3 
Biotin & 
Streptavidin 
APC-efluor 780 
Streptavidin only 
control  
eBioscience 
RORγt B2D PerCP-efluor
 
710  Rat IgG1 κ eBioscience 
IL-17A  eBio17B7 
Pacific blue or 
PE  
Rat IgG2a κ eBioscience 
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Figure E1  
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Figure E2 
 
